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Introduction
Cancer in childhood is rare. The most recent
SEER Cancer Statistics Review, released in
April 2018 and covering 2011–2015, shows that
for ages 0–14 the incidence of all cancer sites was
16.4 per 100,000 children, with mortality 2.1 per
100,000. Five-year relative survival for the same
age group was 83.8% for years 2008–2014 [1].
(Rates from the European Cancer Information
System are similar but are currently available
only to 2012.) As of 2015, 1 in 750 of the adult
population of the United States was a long-term
survivor of childhood cancer [1, 2]. Cancer is
more common after puberty, with incidence ris-
ing from 12.9 for ages 5–9 to 23.3 for ages 15–19 in
the United States for years 2011–2015 [1], and
many of these patients will be cured by combina-
tion treatment, with surgery, chemotherapy, and
radiotherapy. Long-term survivors are neverthe-
less at risk of developing a number of late sequelae
[3], including impaired fertility, adverse preg-
nancy outcomes, and health problems in offspring
[4–6]. Loss of fertility is one of the most devastat-
ing consequences of radiotherapy for these young
patients, who, having overcome their disease,
have expectations of a normal reproductive life.
Normal Ovarian Development
and Follicular Depletion
Current understanding of the human ovarian
reserve is that the ovary establishes several hun-
dred thousand nongrowing follicles (NGFs) by
followed by a decline in the population by meno-
pause, when approximately 800 remain at an
average age of 50–51 [7]. With approximately
450 ovulatory monthly cycles in the normal
human reproductive life span, this progressive
decline in NGF numbers is attributed to follicle
death by apoptosis. The Wallace–Kelsey model
of human ovarian reserve from conception to
menopause best fits the combined histological
evidence that has been described [8, 9] and vali-
dated using external data [7] (Figure 3.1). This
model allows us to estimate the number of NGFs
present in the ovary at any given age, and it
suggests that 81% of the variance in NGF popu-
lations is due to age alone. Further analysis
demonstrates that 95% of the NGF population
variation is due to age alone for ages up to 25.
The remaining 5% is due to factors other than
age, e.g. smoking, body mass index (BMI), parity,
and stress. We can speculate that as chronologi-
cal age increases, factors other than age become
more important in determining the rate at which
NGFs are lost through apoptosis.
There is speculation that this widely held tenet
of mammalian ovarian function may require revi-
sion. A report in 2004 suggested the presence of
germ stem cells in the adult mouse ovary [10], with
two subsequent reports by the same group suggest-
ing the ability of bonemarrow–derived cells to give
rise to new immature oocytes [11, 12]. More
recently, another group has identified the presence
of proliferative and culturable female germline
stem cells in newborn and adult mouse ovaries
[13]. Strikingly, when these cells (transgenically
labeled) were injected into a chemotherapy-
treated ovary, they became enclosed within follicles
and offspring bearing the transgene were pro-
duced. These data provide a basis for reevaluating
the regenerative capacity of the mammalian ovary
and new approaches for overcoming fertility loss.
While the emerging evidence thus appears to pro-
vide evidence in support of the existence of germ
stem cells within the adult mammalian ovary, there
is no robust evidence to date that these cells con-
tribute to follicle formation leading to viable eggs
[14]. There is evidence that significant NGF popu-
lation regeneration can occur in extreme situations
in the human ovary [15], but the Wallace–Kelsey
model of ovarian follicle decline provides no
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supporting evidence of neo-oogenesis in normal
human physiological aging.
Radiation and the Hypothalamic–
Pituitary–Ovarian Axis
The ovaries may be damaged following total body,
abdominal, or pelvic irradiation [16], and the
extent of the damage is related to the radiation
dose, fractionation schedule, and age at the time
of treatment [17–19]. The human oocyte is sensi-
tive to radiation, with an estimated LD50 of less
than 2 Gy [20]. This is the lethal dose to destroy
50% of NGFs present in the ovary. The number of
NGFs present at the time of treatment, together
with the dose received by the ovaries, will deter-
mine the “fertile window” and influence the age of
premature ovarian insufficiency (POI). Long-
term ovarian failure has been reported in 90% of
patients after total body irradiation (TBI) (10.00–
15.75 Gy) and in 97% of females treated with total
abdominal irradiation (20–30 Gy) during child-
hood [21–23]. Our understanding of the LD50 of
the human oocyte has made it possible to estimate
the age at which POI may occur (Figure 3.2).
Furthermore, we have estimated the sterilizing
dose following any given dose of radiotherapy at
any given age, based upon the Wallace–Kelsey
model for NGF decline (Figure 3.3) [24, 25].
This will help clinicians provide accurate infor-
mation when counseling women about fertility
following treatment for childhood cancer.
Gonadotropin deficiency following high-dose cra-
nial irradiation (more than 24 Gy in the treatment
of brain tumors) manifests as delayed puberty or
absent menses and can be treated by hormone
replacement therapy. Interestingly, early puberty
is often reported in females with cranial radiation
doses of less than 24 Gy [26]. However, we have
shown a subtle decline in hypothalamic– pitui-
tary–ovarian function following low-dose cranial
radiotherapy (18–24 Gy). This is characterized by
decreased luteinizing hormone (LH) secretion
throughout the cycle, an attenuated LH surge,
and short luteal phases [27], which may compro-
mise reproductive function. Cranial radiotherapy
is also associated with increased risk of oligome-
norrhea, reduced estradiol, and increased prolac-
tin in survivors [28, 29]. Recent data confirm
lower fertility in childhood cancer survivors trea-
ted with either hypothalamic/pituitary irradiation
more than 22 Gy or ovarian/uterine irradiation
more than 5 Gy [30, 31]. Nowadays, the most
commonly used fertility preservation measure is
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Figure 3.1 The Wallace–Kelsey model of NGF decline from birth to age 60. The average ovary contains 300,000 NGFs at birth,
declining to 100,000 at age 20, with about 800 remaining at average age of menopause (50–51 years)
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the surgical transposition of the ovaries outside
the irradiation field before the initiation of pelvic
radiation in adults with gynecological malignan-
cies [24]. This approach may be considered for
patients not planning to receive high-dose sys-
temic chemotherapy. Surgery is effective at pro-
tecting the ovaries from direct irradiation
damage, but fertility may be affected by scatter
radiation, by damage to the ovarian vasculature
during surgery, or by torsion of the transposed
ovary. To avoid this, ovarian tissue cryopreserva-
tion may be considered at the same time as
oophoropexy.
Radiation and the Uterus
The uterus is at significant risk of damage following
abdominal irradiation, pelvic irradiation, or TBI in
a dose- and age-dependent manner [32]. Uterine
function may be impaired following radiation
doses of 14–30 Gy as a consequence of disruption
to uterine vasculature and musculature elasticity
[23]. Even lower doses of irradiation, as in TBI,
have been reported to cause impaired growth and
blood flow [33]. The clinical consequences are
increased risk of miscarriage and premature deliv-
ery [22]. A uterine contribution to an inability to
conceive following radiotherapy is not clear but
seems likely.
A small number of studies have been reported
that attempted to improve uterine function in
survivors of cancer with POI. In young adult
women previously treated with TBI, physiological
sex steroid replacement therapy improves uterine
function (blood flow and endometrial thickness)
and may potentially allow them to benefit from
assisted reproductive technologies [33]. Larsen
et al. studied uterine volume in 100 childhood
cancer survivors and assessed uterine response
to high-dose estrogen replacement therapy in
three patients with ovarian failure and reduced
uterine volume following abdominal and/or pel-
vic irradiation [34]. There was no significant dif-
ference in uterine volume, endometrial thickness,
or uterine artery blood flow following sex steroid
treatment, suggesting that higher doses of pelvic
radiation cause greater damage than lower doses
(as in TBI), and that this damage may be irrever-
sible.While data are sparse for the childhood case,
there is good evidence that adult women treated
0 5 10 15 20 25 30




































Figure 3.2 Predicted age at POI for known age and known dose to the ovary. A 5-year-old with average NGF population treated
with 1 Gy has predicted POI at age 42, losing about 8 years of reproductive life span; the same child treated with 12 Gy has predicted
POI at age 12, indicating consideration of the use of fertility preservation techniques. The predictions are modifications of existing
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with radiotherapy to the abdomen are at high risk
of uterine dysfunction leading tomiscarriage, pre-
mature delivery, low birth weight, and placental
abnormalities [35]. There is no current evidence
that the child uterus is inherently better protected
from the effects of radiotherapy.
Testicular Function
In males, testicular damage can involve the
somatic cells of the testis (Sertoli, peritubular
myoid, and Leydig cells) or the germ cells.
Spermatogonia are generally more radiosensitive
and prone to undergo apoptosis than somatic
cells [36]. Sertoli cells are responsible for nurtur-
ing developing germ cells, and Leydig cells pro-
duce testosterone. Recent data have revealed the
essential contribution of peritubular myoid cells
in mediating the effect of testosterone on sper-
matogenesis. Gonadal damage in males treated
for cancer can result from either systemic che-
motherapy or radiotherapy to a field that
includes the testes. Cytotoxic treatment targets
rapidly dividing cells, and it is therefore not
surprising that spermatogenesis is impaired
after treatment for cancer. The exact mechanism
of this damage is uncertain, but it appears to be
linked to depletion of the proliferating germ
cell pool and associated stem spermatogonial
cells. Although the prepubertal testis does not
complete spermatogenesis and produce mature
spermatozoa, cytotoxic treatment given to pre-
pubertal boys may impair future fertility.
Importantly, the prepubertal testis is susceptible
to cytotoxic damage.
Radiotherapy to the Testis
In males, radiation doses as low as 0.1–1.2 Gy can
impair spermatogenesis, with doses over 4 Gy
causing permanent azoospermia. The somatic
cells of the testis are more resistant than the
germ cells, and Leydig cell dysfunction is not
observed until 20 Gy in prepubertal boys and
30 Gy in sexually mature males [37].
Within the pediatric and adolescent age group,
testicular damage occurs with direct irradiation to
the testes, for example in the management of
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Figure 3.3 Themean and effective sterilizing doses of radiation to the human ovary. The blue line shows the radiation in Gy needed
to sterilize 50% of subjects. The red line shows the radiation in Gy needed to sterilize 97.5% of subjects. The predictions are derived
from the Wallace–Kelsey model of NGF population in healthy females [9], and the estimated radiosensitivity of the human NGFs [20]
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leukemia [38]. In patients with leukemic infiltration
of their testes, radiation doses of 24 Gy are used, and
this results in permanent azoospermia [39]. Total
body irradiation applied as conditioning treatment
before bone marrow transplantation (BMT) also
irradiates the testes. However, the effects of this can
be difficult to elucidate as it is usually given concur-
rently with alkylating agents, but doses of 9–10 Gy
have produced gonadal dysfunction [40].
There have been many advances in technologies
underpinning the delivery of radiotherapy, includ-
ing intensity-modulated radiotherapy (IMRT),
volumetric-modulated arc therapy (VMAT), and
proton therapy (PT). There are case reports that
suggest, for example, that IMRT can lead to
a reduction in acute affects [41], and there is initial
evidence that VMAT also reduces acute affects with
PT reducing the risk of secondary malignancies in
younger patients [42]. However, robust and large-
scale clinical trial evidence is lacking in this area,
and hence accurate survey and meta-analysis stu-
dies are not yet possible. More data are needed
before the precise effects of modern radiotherapy
to the testis can be reliably estimated.
Summary
While many children and adults diagnosed with
cancer can now realistically hope for long-term
survival, they must often live with the conse-
quences of their treatment. Infertility is one of
the most devastating adverse effects of cancer
treatment in this patient group. Radiotherapy
can significantly impair future fertility, and
treatments for certain cancers can be sterilizing
[24]. Although predicting individual fertility fol-
lowing treatment is challenging due to the lack
of biomarkers in children that indicate future
fertility, we can both calculate sterilizing doses
and predict age at POI on the assumption that
the patient had close to average untreated ferti-
lity potential. Nevertheless, further epidemiolo-
gical studies and investigation of markers
indicating gonadal damage may be of use to
our patients.
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